Kazazian Asset Management’s Blueprint Medicines BPMC Stock Holding History

Kazazian Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$563K	Hold	7,662	–	–	0.76%	32
2019 Q2	$723K	Sell	7,662 -1,000	-12%	-$82.5K	0.86%	29
2019 Q1	$693K	Sell	8,662 -9,866	-53%	-$729K	0.96%	26
2018 Q4	$999K	Sell	18,528 -10,508	-36%	-$639K	1.35%	21
2018 Q3	$2.27M	Hold	29,036	–	–	2.12%	13
2018 Q2	$1.84M	Buy	29,036 +390	+1%	+$31K	1.69%	14
2018 Q1	$2.63M	Hold	28,646	–	–	2.75%	9
2017 Q4	$2.16M	Buy	28,646 +3,911	+16%	+$275K	2.21%	12
2017 Q3	$1.72M	Buy	24,735 +1,462	+6%	+$78.1K	2.11%	12
2017 Q2	$1.18M	Buy	+23,273	New	+$988K	1.78%	14

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Kazazian Asset Management's BPMC Position: Q3 2019 in Review

Kazazian Asset Management held its Blueprint Medicines (BPMC) position steady in Q3 2019 at 7,662 shares worth $563K. The position accounts for 0.76% of the portfolio, ranked #32.

Kazazian Asset Management first reported a position in BPMC in Q2 2017 and has held it in 10 quarters since. The position peaked at $2.63M in Q1 2018. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2019.

Kazazian Asset Management held 7,662 shares of Blueprint Medicines worth $563K as of Q3 2019.
Kazazian Asset Management left its Blueprint Medicines share count unchanged in Q3 2019.
Blueprint Medicines made up 0.76% of Kazazian Asset Management's portfolio in Q3 2019, its #32 holding.
Kazazian Asset Management first reported a position in Blueprint Medicines in Q2 2017 and has held it in 10 quarters since.
Kazazian Asset Management's Blueprint Medicines position peaked at $2.63M in Q1 2018.
220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2019.

Based on Kazazian Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.